Your SlideShare is downloading. ×
Satinder Pal Singh Grewal MD
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Satinder Pal Singh Grewal MD

1,167
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,167
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Satinder Pal Singh Grewal MD Rajeev Jain, MD Dilraj Grewal MBBS Gagandeep S Brar MD Safety and Efficacy of OculusGen Biodegradable Collagen Matrix Implant in Phacotrabeculectomy Surgery GREWAL EYE INSTITUTE CHANDIGARH, INDIA
  • 2. Financial Disclosures None of the authors have any financial interest in this presentation
  • 3.
    • T o present the preliminary results of a pilot study that evaluating the safety and efficacy of OculusGen Biodegradable Collagen Matrix Implant designed to improve the regenerating tissue-remodeling in glaucoma patients with cataract undergoing combined phacotrabeculectomy surgery.
    Purpose This study was registered with ClinicalTrials.gov: Identifier NCT00477685
  • 4.
    • Long-term intraocular pressure (IOP) control following trabeculectomy may be limited by filtration failure, due to scarring at the level of the conjunctiva-Tenon’s-episcleral interface, the scleral flap or its overlying episclera, or the internal ostium
    • Clinically, mitomycin-C (MMC), 5-fluorouracil, and corticosteroids have all been used to inhibit fibroblast proliferation to prevent scar development after glaucoma surgery.However they are associated with the risk for late postoperative complications, including wound leakage, hypotony, and maculopathy. 1,2,3
    • Sinnreich Z, Barishak R, Stein R. Leaking filtering blebs. Am J Ophthalmol. 1978;86:345–349.
    • Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol. 1992;114:544–553
    • Sinnreich Z, Barishak R, Stein R. Leaking filtering blebs. Am J Ophthalmol. 1978;86:345–349.
    Introduction
  • 5.
    • The use of tissue bioengineering to prevent scar prevention has been described. 4,5,6,7 The application of three-dimensional, collagen-glycosaminoglycan copolymers can lead to random and relatively loose reorganization of regenerating myofibroblasts, fibroblasts, and the secreted extracellular matrix (i.e., collagen), reducing scar formation.
    • These biodegradable implants may simultaneously provide physical resistance to overfiltration in the early stages and progressively may reduce this resistance as the implant degrades and a random connective tissue matrix permeates the spaces within the implant to create a loosely organized bleb structure.
    Introduction
    • Yannas IV, Lee E, Orgill DP, Skrabut EM, Murphy GF. Synthesis and characterization of a model extracellular matrix that induces partial regeneration of adult mammalian skin. Proc Nat Acad Sci USA. 1989;86:933–937.
    • Yannas IV. Studies on the biological activity of the dermal regeneration template. Wound Repair Region. 1998;6:518–524.
    • Chen HS, Ritch R, Krupin T, Hsu WC. Control of filtering bleb structure through tissue bioengineering: An animal model.Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5310-4.
    • Young MJ, Borras T, Walter M, Ritch R (2005) Potential applications of tissue engineering to glaucoma. Arch Ophthalmol 123:1725–173
    • Hsu WC, Ritch R, Krupin T, Chen HS. Tissue bioengineering for surgical bleb defects: an animal study. Graefes Arch Clin Exp Ophthalmol. 2008 Feb 12 [Epub ahead of print]
  • 6. Structure: Biodegradable Collagen Matrix Implant Scanning electron microscopic image of collagen matrix. A drug-free, biodegradable, porous collagen matrix of 1% collagen/C-6-S copolymer (OloGen) with a 7-mm diameter and a 4-mm thickness was used.
    • In this study a three-dimensional biodegradable collagen matrix was placed in the subconjunctival space and on top of the scleral flap to achieve better postoperative IOP control and to reduce the risk for early shallow anterior chamber.
  • 7.
    • 5 patients underwent combined trabeculectomy with the OculusGen Biodegradable Collagen Matrix Implant in one eye for refractory glaucoma
    • Refractory glaucoma was defined as having previously failed medical, laser or surgical treatment, and phacoemulsifcation with Acrylic IOL impant (AMO AR-40).
    • The OculusGen was implanted on the top of the scleral flap at the limbus before closing the conjunctival wound during trabeculectomy operations.
    • Intraocular pressure (IOP), bleb characteristics and post-operative complications were assessed before and after surgery.
    • Bleb photographs were analyzed at all post-operative visits according to the Moorfields Bleb-Grading System for the parameters of area (grades 1-5), height (grades 1-4) and vascularity (grades 1-5).
    Methods
  • 8.
    • Age 30 years or older
    • No previous intraocular surgery
    • Uncontrolled glaucoma, with failed medical and laser treatment, requiring trabeculectomy.
    • Known allergic reaction to porcine collagen.
    • Subject is on warfarin and discontinuation is not recommended.
    • Patients with:
      • Normal tension glaucoma,
      • Uveitic glaucoma,
      • Sphakic or pseudophakic glaucoma,
      • Neovascular glaucoma
      • Secondary glaucoma.
    • Ocular infection within 14 days prior to trabeculectomy.
    • Pregnant or breast-feeding women
    Inclusion Criteria: Exclusion Criteria: Methods
  • 9. Surgical Method of Implantation Graphics from www.oculusgen.com
  • 10. Surgical Method of Implantation Graphics from www.oculusgen.com
      • Hsu WC, Ritch R, Krupin T, Chen HS. Tissue bioengineering for surgical bleb defects: an animal study. Graefes Arch Clin Exp Ophthalmol. 2008 Feb 12 [Epub ahead of print]
    • Positioning of implant in respect to the scleral flap and the conjunctival wound.
    • Double arrow points to Conjunctival defect over the area above the implant.
  • 11. Results
    • The study population included 4 Males and 1 Female
    • Average age was 56.3 ± 9.6 yrs
    • The mean preoperative IOP was 35.7 ± 7.8 mmHg.
    • Postoperatively, the mean IOP at 4 months follow-up for all eyes had a 54.3% reduction (p < 0.05) to 16.3 ±2.1 mmHg.
    • There were no significant intra-operative or post-operative complications in any patients.
  • 12. Conclusions
    • The short-term preliminary results of this study indicate that the OculusGen implantation in combined phaco-trabeculectomy could potentially provide a safe and effective therapeutic preventing wound failure following trabeculectomy surgery.
    • The OculusGen helps to modulate wound healing response following glaucoma filtering surgery.
    • However a larger study with a longer follow-up period is required to confirm these observations.
    • Biodegradable Collagen Matrix implants can help in achieving a successful trabeculectomy without antifibrotic medication,controlling both the physical and physiologic aspects of wound healing.